Novo Enhances Obesity Treatment Strategy with Over $800 Million Deep Collaboration with Apple for Oral, Non-Incretin Therapeutics

Novo Enhances Obesity Treatment Strategy with Over $800 Million Deep Collaboration with Apple for Oral, Non-Incretin Therapeutics

Novo Enhances Obesity Treatment Strategy with Over $800 Million Deep Collaboration with Apple for Oral, Non-Incretin Therapeutics